Thus, even though particular somatic hOCT1 mutations have been recently identified in hepatocarcinomas (Herraez et al., 2013), decreased expression of this drug transporter has also been reported when compared to adjacent non-tumor tissue (Martinez-Becerra et al., 2012). This evidence concerns the gene SLC22A1 and neoplasm.